The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement
Open accessAbstract
BACKGROUND: Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear. METHODS: We randomly assigned 1644 patients without an established indication for oral anticoagulation after successful TAVR to receive rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3 months) (rivaroxaban group) or aspirin at a dose of 75 to 100 mg daily (with clopidogrel at a dose of 75 mg daily for the first 3 months) (antiplatelet group). The primary efficacy outcome was the composite of death or thromboembolic events. The primary safety outcome was major, disabling, or life-threatening bleeding. The trial was terminated prematurely by the data and safety monitoring board because of safety concerns. RESULTS: After a median of 17 months, death or a first thromboembolic event (intention-to-treat analysis) had occurred in 105 patients in the rivaroxaban group and in 78 patients in the antiplatelet group (incidence rates, 9.8 and 7.2 per 100 person-years, respectively; hazard ratio with rivaroxaban, 1.35; 95% confidence interval [CI], 1.01 to 1.81; P = 0.04). Major, disabling, or life-threatening bleeding (intention-to-treat analysis) had occurred in 46 and 31 patients, respectively (4.3 and 2.8 per 100 person-years; hazard ratio, 1.50; 95% CI, 0.95 to 2.37; P = 0.08). A total of 64 deaths occurred in the rivaroxaban group and 38 in the antiplatelet group (5.8 and 3.4 per 100 person-years, respectively; hazard ratio, 1.69; 95% CI, 1.13 to 2.53). CONCLUSIONS: In patients without an established indication for oral anticoagulation after successful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy. (Funded by Bayer and Janssen Pharmaceuticals; GALILEO ClinicalTrials.gov number, NCT02556203.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
Leon, M. B., Smith, C. R., Mack, M., Miller, D. C., Moses, J. W., Svensson, L. G., Tuzcu, E. M., Webb, J. G., Fontana, G. P., Makkar, R. R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008232 · Cited by 7,205
Self-citationTranscatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
Smith, C. R., Leon, M. B., Mack, M. J., Miller, D. C., Moses, J. W., Svensson, L. G., Tuzcu, E. M., Webb, J. G., Fontana, G. P., Makkar, R. R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103510 · Cited by 6,345
Self-citation2017 ESC/EACTS Guidelines for the management of valvular heart disease
Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Rodriguez Muñoz, D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx391 · Cited by 6,243
Self-citationTranscatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
Leon, M. B., Smith, C. R., Mack, M. J., Makkar, R. R., Svensson, L. G., Kodali, S. K., Thourani, V. H., Tuzcu, E. M., Miller, D. C., Herrmann, H. C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1514616 · Cited by 5,053
Self-citationTranscatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
Mack, M. J., Leon, M. B., Thourani, V. H., Makkar, R., Kodali, S. K., Russo, M., Kapadia, S. R., Malaisrie, S. C., Cohen, D. J., Pibarot, P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814052 · Cited by 4,847
Self-citationTranscatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
Popma, J. J., Deeb, G. M., Yakubov, S. J., Mumtaz, M., Gada, H., O’Hair, D., Bajwa, T., Heiser, J. C., Merhi, W., Kleiman, N. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816885 · Cited by 3,674
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.536 · Cited by 3,523
Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients
Reardon, M. J., Van Mieghem, N. M., Popma, J. J., Kleiman, N. S., Søndergaard, L., Mumtaz, M., Adams, D. H., Deeb, G. M., Maini, B., Gada, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700456 · Cited by 3,009
Self-citationTranscatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis
Adams, D. H., Popma, J. J., Reardon, M. J., Yakubov, S. J., Coselli, J. S., Deeb, G. M., Gleason, T. G., Buchbinder, M., Hermiller, J., Kleiman, N. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400590 · Cited by 2,902
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation
Kappetein, A. P., Head, S. J., Généreux, P., Piazza, N., van Mieghem, N. M., Blackstone, E. H., Brott, T. G., Cohen, D. J., Cutlip, D. E., van Es, G.-A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.001 · Cited by 1,668
Self-citationPossible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves
Makkar, R. R., Fontana, G., Jilaihawi, H., Chakravarty, T., Kofoed, K. F., De Backer, O., Asch, F. M., Ruiz, C. E., Olsen, N. T., Trento, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509233 · Cited by 1,051
Self-citationChakravarty, T., Søndergaard, L., Friedman, J., De Backer, O., Berman, D., Kofoed, K. F., Jilaihawi, H., Shiota, T., Abramowitz, Y., Jørgensen, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30757-2 · Cited by 909
Self-citationProsthetic Heart Valve Thrombosis
Dangas, G. D., Weitz, J. I., Giustino, G., Makkar, R., & Mehran, R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.958 · Cited by 502
Self-citationTranscatheter Aortic Valve Thrombosis
Hansson, N. C., Grove, E. L., Andersen, H. R., Leipsic, J., Mathiassen, O. N., Jensen, J. M., Jensen, K. T., Blanke, P., Leetmaa, T., Tang, M., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.08.010 · Cited by 367
Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement
De Backer, O., Dangas, G. D., Jilaihawi, H., Leipsic, J. A., Terkelsen, C. J., Makkar, R., Kini, A. S., Veien, K. T., Abdel-Wahab, M., Kim, W.-K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911426 · Cited by 293
Self-citationClinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement
Jose, J., Sulimov, D. S., El-Mawardy, M., Sato, T., Allali, A., Holy, E. W., Becker, B., Landt, M., Kebernik, J., Schwarz, B., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.01.045 · Cited by 257
Bioprosthetic Valve Thrombosis
Puri, R., Auffret, V., & Rodés-Cabau, J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.051 · Cited by 188
Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement
Dangas, G., Lefèvre, T., Kupatt, C., Tchétché, D., Schäfer, U., Dumonteil, N., Webb, J. G., Colombo, A., Windecker, S., ten Berg, J. M., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.003 · Cited by 124
Self-citationLong-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use
Overtchouk, P., Guedeney, P., Rouanet, S., Verhoye, J., Lefèvre, T., BELLE, E. V., Eltchaninoff, H., Gilard, M., Leprince, P. N., Iung, B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.1045 · Cited by 117
Self-citationWindecker, S., Tijssen, J. G. P., Giustino, G., Guimarães, A. H. C., Mehran, R., Valgimigli, M., Vranckx, P., Welsh, R. C., Baber, U., van Es, G., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.10.017 · Cited by 104
Self-citationCerebral Embolism During Transcatheter Aortic Valve Replacement
BELLE, E. V., Hengstenberg, C., Lefèvre, T., Kupatt, C., Debry, N., Hüsser, O., Pontana, F., Kuchcinski, G., Deliargyris, E., Mehran, R., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.05.006 · Cited by 59
Self-citation
Cited by
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Self-citation2021 ESC/EACTS Guidelines for the management of valvular heart disease
Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab395 · Cited by 5,685
Self-citationOtto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686
Self-citationKleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000932 · Cited by 2,449
Self-citation
Metadata
- Authors
- Dangas, G. D., Tijssen, J. G. P., Wöhrle, J., Søndergaard, L., Gilard, M., Möllmann, H., Makkar, R. R., Herrmann, H. C., Giustino, G., Baldus, S., De Backer, O., Guimarães, A. H. C., Gullestad, L., Kini, A., von Lewinski, D., Mack, M., Moreno, R., Schäfer, U., Seeger, J., Tchétché, D., Thomitzek, K., Valgimigli, M., Vranckx, P., Welsh, R. C., Wildgoose, P., Volkl, A. A., Zazula, A., van Amsterdam, R. G. M., Mehran, R., & Windecker, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-09
- Volume
- 382
- Issue
- 2
- Pages
- 120-129
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2987620153
- Cited by
- 552
- References
- 24
- FWCI
- 52.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.